Tekmira Pharmaceuticals Corporation  

(Public, NASDAQ:TKMR)   Watch this stock  
Find more results for TKMR
-0.93 (-6.65%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.82 - 14.20
52 week 4.46 - 31.48
Open 13.76
Vol / Avg. 801,346.00/921,846.00
Mkt cap 286.87M
P/E     -
Div/yield     -
EPS -0.87
Shares     -
Beta 0.85
Inst. own     -
Mar 24, 2014
Q4 2013 Tekmira Pharmaceuticals Corporation Earnings Release (Estimated)
Feb 11, 2014
Tekmira Pharmaceuticals Corporation at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    


Suite 100, 8900 Glenlyon Parkway
+1-604-4193200 (Phone)
+1-604-4193201 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. On March 1, 2012, it announced that the Company had secured a license from Alnylam to develop TKMALDH2, an RNAi therapeutic that utilizes Tekmira's LNP for the treatment of Alcohol Dependence (AD). Its lead oncology product candidate, TKM-PLK1, targets PLK1, a protein involved in tumor cell proliferation and a validated oncology target. On February 8, 2012, it announced that Phase I clinical trial for TKM-Ebola had been initiated. The Phase 1 TKM-Ebola clinical trial is a placebo-controlled, single-blind, single-ascending dose study with additional multiple-ascending dose cohorts in healthy human volunteers. In the field of RNAi therapeutics, the Company has licensed its LNP delivery technology to Alnylam Pharmaceuticals, Inc. and Merck & Co., Inc.

Officers and directors

Daniel L. Kisner M.D. Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Mark J. Murray Ph.D. President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Bruce G. Cousins Chief Financial Officer, Executive Vice President
Bio & Compensation  - Reuters
Ian MacLachlan Ph.D. Executive Vice President, Chief Technical Officer
Bio & Compensation  - Reuters
Michael J. Abrams Ph.D. Executive Vice President and Chief Discovery Officer
Age: 51
Bio & Compensation  - Reuters
Paul A. Brennan Senior Vice President - Business Development
Bio & Compensation  - Reuters
Mark Kowalski M.D., Ph.D. Chief Medical Officer, Senior Vice President
Age: 57
Bio & Compensation  - Reuters
Peter Lutwyche Ph.D. Senior Vice President - Pharmaceutical Development
Bio & Compensation  - Reuters
Diane Gardiner Vice President - Human Resources
Bio & Compensation  - Reuters
R. Hector MacKay-Dunn Q.C. Corporate Secretary
Bio & Compensation  - Reuters